Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis

Background Fondaparinux sodium has been compared with low‐molecular‐weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis. However, the results from these studies are inconsistent in terms of efficacy and safety to reach a clinical decision. The objecti...

Full description

Bibliographic Details
Main Authors:	Arun Kumar, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, Wenchen Wu
Format:	Article
Language:	English
Published:	Wiley 2019-05-01
Series:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:	effectiveness fondaparinux low molecular weight heparin prevention safety systematic review
Online Access:	https://www.ahajournals.org/doi/10.1161/JAHA.119.012184

Similar Items

Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis
by: Kušić Jovana, et al.
Published: (2016-01-01)

Successful use of fondaparinux for perioperative bridging in a patient with a mechanical heart valve and heparin-induced thrombocytopenia
by: C R Pruthvi, et al.
Published: (2019-01-01)

Retrospective Analysis of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Women With Recurrent Spontaneous Abortion
by: Long Zhao, et al.
Published: (2021-10-01)

Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: A three-patient case series report
by: Jitka Rychlíčková, et al.
Published: (2023-02-01)

Comparative Evaluation of Efficacy, Safety and Haemostatic Parameters of Enoxaparin and Fondaparinux in Unstable Coronary Artery Disease
by: Sanjay Shah, et al.
Published: (2014-01-01)

Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study
by: Tianxiang Yang, et al.
Published: (2023-07-01)

Does ‘heparin-induced thrombocytopenia’ hit our minds?
by: Arun R. Thangavel, et al.
Published: (2016-08-01)

Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
by: Haibier A, et al.
Published: (2023-11-01)

Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study
by: Donglin Fu, et al.
Published: (2022-06-01)

Influence of fondaparinux versus nadroparin calcium thromboprophylaxis on clinical parameters following total knee arthroplasty
by: Zdravka Mihaljević, et al.
Published: (2016-01-01)

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland
by: Lorenzo A. Alberio, et al.
Published: (2020-04-01)

Safety and efficacy of thromboprophylaxis with fondaparinux in elderly acutely ill medical patients with renal impairment: a retrospective single center study
by: Federico Silvestri, et al.
Published: (2013-12-01)

Fondaparinux
by: G. Airoldi, et al.
Published: (2013-05-01)

Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban
by: Farheen Manji, et al.
Published: (2020-01-01)

Safety and effectiveness of fondaparinux as a postpartum thromboprophylaxis during puerperium among muslim women: A single centre prospective study
by: Normaliza Muhamad, et al.
Published: (2022-09-01)

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis
by: Pravesh Kumar Bundhun, et al.
Published: (2017-05-01)

Heparin and SARS-CoV-2: Multiple Pathophysiological Links
by: Pierpaolo Di Micco, et al.
Published: (2021-12-01)

Novel fondaparinux protocol for anticoagulation therapy in adults with renal failure and suspected heparin-induced thrombocytopenia: a retrospective review of institutional protocol
by: Dania Ghaziri, et al.
Published: (2023-01-01)

Contribution of novel anticoagulants fondaparinux and dabigatran to venous thromboembolism prevention
by: Antonijević Nebojša, et al.
Published: (2015-01-01)

Cutaneous reactions to heparin therapy: when are they caused by heparin allergy?
by: Giuliana Zisa, et al.
Published: (2013-03-01)

Antithrombotic drugs with adjuvant action against COVID-19
by: Pierpaolo Di Micco, et al.
Published: (2020-12-01)

Old and New anticoagulants: The beginning of a new era?
by: Fidel Cáceres Loriga, et al.
Published: (2011-01-01)

Risk factors for bleeding in patients receiving fondaparinux after colorectal cancer surgery
by: Jongsung Pak, et al.
Published: (2017-10-01)

Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase
by: Mohamed S. Abdel-Bakky, et al.
Published: (2023-06-01)

Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series
by: Mégane Tanguay, et al.
Published: (2022-07-01)

Effect of fondaparinux on viability and ischemia reperfusion injury in the abdominal perforator flap
by: Guler Gamze Eren Ozcan, et al.
Published: (2020-01-01)

THE USE OF ENOXAPARIN IN ACUTE CORONARY SYNDROME
by: E. A. Smirnova, et al.
Published: (2017-01-01)

FONDAPARINUX USAGE IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME
by: G. V. Mardaryan, et al.
Published: (2015-09-01)

Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study
by: Lei Wang, et al.
Published: (2023-05-01)

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
by: Vincenzo Russo, et al.
Published: (2020-11-01)

Efficacy and risks of fondaparinux 7.5 mg for deep vein thrombosis after total knee arthroplasty
by: Sho Nojiri, et al.
Published: (2019-02-01)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
by: Flávio Luís Garcia, et al.
Published: (2015-08-01)

Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India
by: Saumitra Ray, et al.
Published: (2023-04-01)

The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery
by: Hiroyuki Ohta, et al.
Published: (2019-06-01)

Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)
by: Qinan Yin, et al.
Published: (2024-03-01)

Clinical experience with fondaparinux in antiaggregate patients undergoing total hip and knee arthroplasty
by: Guido Grappiolo, et al.
Published: (2013-09-01)

Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation
by: Abdullah Pandor, et al.
Published: (2019-12-01)

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
by: Cardillo G, et al.
Published: (2021-02-01)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
by: Alpesh Amin, et al.
Published: (2023-06-01)

The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
by: Matthew Y. Wei, et al.
Published: (2015-11-01)